Niki BioSolutions closes DiamiR merger; acquired firm posts FY2026 net loss and going-concern doubt

Aptorum Group Ltd

Merger closed July 20, 2026; DiamiR Biosciences became a wholly-owned subsidiary of Niki BioSolutions (formerly Aptorum Group).
DiamiR FY2026 net loss of $659,936 vs $743,235 in FY2025; revenue grew to $190,355 from $631,729.
Auditor cites significant working capital deficiency and needs to raise funds; going-concern doubt raised.
As of May 31, 2026, DiamiR had cash of $112,690, current assets $345,250 and current liabilities $2,191,803.
DiamiR's outstanding convertible notes are expected to convert to Niki common shares under the merger agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.